Evidence in Populations Under‑Represented in Clinical Trials

Evidence is sought to understand the use, outcomes, and lived experiences of individuals receiving CAB + RPV LA, particularly among populations not represented or underrepresented in pivotal clinical trials. Populations of Interest is open and may include, but not limited to: women across the age and reproductive continuum, individuals who have fallen out of care (where CAB + RPV LA may facilitate re-engagement in care opportunities), adherence‑challenged individuals, long‑term survivors (i.e., individuals having a HIV diagnosis prior to 1996), older adults (EU region only), treatment naive individuals switching soon after attaining initial viral suppression with oral ART.

ViiV ISR Area Of Interest Overview

Drug/Product Alignment

ViiV Products in Scope:	Cabotegravir
Treatment Type:	Long Acting-Treatment
Specify the Treatment Type:

Area of Interest/DataGap Description

Core Focus Area:	Efficacy/Effectiveness, Quality of LIfe
Example Research Question(s):

Desirable Study Parameters

Populations of Interest:	All Patient Types
Geographical Regions:	Global

Version 20250909-disp

- Back to Top -

Evidence in Populations Under‑Represented in Clinical Trials

ViiV ISR Area Of Interest Overview

Pure Substance Request

Investigator Sponsored Study (ISS)

Collaborative Study